Cornercap Investment Counsel’s CytomX Therapeutics CTMX Stock Holding History

Cornercap Investment Counsel’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-41,458	Closed	-$48.9K	–	484
2024 Q3	$48.9K	Sell	41,458 -39,133	-49%	-$49.7K	0.01%	509
2024 Q2	$98.3K	Sell	80,591 -761	-0.9%	-$1.51K	0.02%	571
2024 Q1	$177K	Hold	81,352	–	–	0.03%	575
2023 Q4	$126K	Hold	81,352	–	–	0.02%	556
2023 Q3	$105K	Sell	81,352 -1,063	-1%	-$1.67K	0.02%	534
2023 Q2	$142K	Hold	82,415	–	–	0.02%	538
2023 Q1	$124K	Sell	82,415 -65,939	-44%	-$149K	0.02%	533
2022 Q4	$237K	Hold	148,354	–	–	0.04%	496
2022 Q3	$215K	Buy	148,354 +69,902	+89%	+$108K	0.04%	485
2022 Q2	$144K	Buy	+78,452	New	+$150K	0.03%	508

Other funds holding CTMX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cornercap Investment Counsel's CTMX Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of CytomX Therapeutics (CTMX) in Q4 2024, closing a stake of 41,458 shares — an estimated $48.9K sold.

Cornercap Investment Counsel first reported a position in CTMX in Q2 2022 and held it in 10 quarters. The position peaked at $237K in Q4 2022. 70 funds tracked by Wall St. Rank hold CTMX as of Q4 2024.

Cornercap Investment Counsel reported no remaining CytomX Therapeutics position as of Q4 2024 after selling out during the quarter.
Cornercap Investment Counsel sold 41,458 CytomX Therapeutics shares in Q4 2024, an estimated $48.9K.
Cornercap Investment Counsel first reported a position in CytomX Therapeutics in Q2 2022 and held it in 10 quarters.
Cornercap Investment Counsel's CytomX Therapeutics position peaked at $237K in Q4 2022.
70 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.